Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription 17.06.2024 5 Aliment Pharmacol Ther 2 Am J Gastroenterol 1 Clin Gastroenterol Hepatol 1 Dig Dis Sci 2 Dis Colon Rectum 2 Gut 4 Inflamm Bowel Dis 2 J Crohns Colitis 1 J Gastroenterol 5 Lancet Gastroenterol Hepatol 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. SEO J, Kim S, Hong SW, Hwang SW, et al
   Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
   Aliment Pharmacol Ther. 2024 Jun 12. doi: 10.1111/apt.18102.
   PubMed         Abstract available
   
   
2. ATTAUABI M, Steenholdt C, Poulsen A, Gubatan J, et al
   Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease.
   Aliment Pharmacol Ther. 2024 Jun 11. doi: 10.1111/apt.18110.
   PubMed         Abstract available
   
   
3. NORDESTGAARD RLM, Wewer MD, Malham M, Wewer V, et al
   Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent - Results from a Danish nationwide cohort study, 2000-2018.
   Aliment Pharmacol Ther. 2024 Jun 10. doi: 10.1111/apt.18106.
   PubMed         Abstract available
   
   
4. FUKUDA T, Yamazaki H, Matsuoka K
   Editorial: Mucosal healing with steroids-Once upon a time in ulcerative colitis. Authors' reply.
   Aliment Pharmacol Ther. 2024 Jun 9. doi: 10.1111/apt.18111.
   PubMed        
   
   
5. BARREIRO-DE ACOSTA M, Rodriguez-Lago I
   Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis.
   Aliment Pharmacol Ther. 2024 Jun 9. doi: 10.1111/apt.18094.
   PubMed        
   
   

   
   Am J Gastroenterol

6. KATHURIA P, Higgins PDR, Berinstein JA
   Timing Is Everything: The Lifesaving Potential of Early Medical Therapy in Acute Severe Ulcerative Colitis.
   Am J Gastroenterol. 2024 Jun 12. doi: 10.14309/ajg.0000000000002867.
   PubMed        
   
   
7. CHUGH R, Long MD, Jiang Y, Weaver KN, et al
   Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
   Am J Gastroenterol. 2024;119:468-476.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

8. WONG SY, Rowan C, Brockmans ED, Law CC, et al
   Perianal fistulizing Crohn's disease-associated anorectal and fistula cancers: systematic review and expert consensus.
   Clin Gastroenterol Hepatol. 2024 Jun 11:S1542-3565(24)00504.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

9. LORES T, Mikocka-Walus A, Andrews JM, Evans S, et al
   Psychological Care for People with Inflammatory Bowel Diseases: Exploring Consumers' Perspectives to Inform Future Service Co-design.
   Dig Dis Sci. 2024;69:1979-1989.
   PubMed         Abstract available
   
   

   
   Dis Colon Rectum

10. LIN VA, Hasselager RP, Fransgaard T, Gogenur I, et al
    Risk Factors for Persistent Postoperative Opioid Use After Surgery for IBD: An Observational Cohort Study.
    Dis Colon Rectum. 2024;67:951-959.
    PubMed         Abstract available
    
    
11. HERREROS MD, Ramirez JM, Otero-Pineiro AM, Marti-Gallostra M, et al
    Use of Darvadstrocel (Allogenic Stem Cell Therapy) for Crohn's Fistulas in Real Clinical Practice: The National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study).
    Dis Colon Rectum. 2024;67:960-967.
    PubMed         Abstract available
    
    

    
    Gut

12. DENNISON TW, Edgar RD, Payne F, Nayak KM, et al
    Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease.
    Gut. 2024 Jun 10:gutjnl-2024-332043. doi: 10.1136/gutjnl-2024-332043.
    PubMed         Abstract available
    
    
13. IACUCCI M, Santacroce G, Majumder S, Morael J, et al
    Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia.
    Gut. 2024 Jun 8:gutjnl-2023-331579. doi: 10.1136/gutjnl-2023-331579.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

14. BURISCH J, Hart A, Sturm A, Rudolph C, et al
    Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey.
    Inflamm Bowel Dis. 2024 Jun 7:izae119. doi: 10.1093.
    PubMed         Abstract available
    
    
15. BROCHARD C, Siproudhis L, Fathallah N, Zerbib P, et al
    Allogenic Stem Cells in Anal Fistulas of Crohn's Disease: From Promising Premises to Real Life Experience.
    Inflamm Bowel Dis. 2024 Jun 11:izae065. doi: 10.1093.
    PubMed         Abstract available
    
    
16. HONAP S, Danese S, Peyrin-Biroulet L
    Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials.
    Inflamm Bowel Dis. 2024 Jun 11:izae131. doi: 10.1093.
    PubMed         Abstract available
    
    
17. BERTANI L, Antonioli L, Fornili M, D'Antongiovanni V, et al
    Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn's Disease: A Prospective Pilot Study.
    Inflamm Bowel Dis. 2024 Jun 12:izae133. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

18. NARULA N, Hamam H, Liu J, Wong ECL, et al
    Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in clinical trials of ulcerative colitis.
    J Crohns Colitis. 2024 Jun 13:jjae092. doi: 10.1093.
    PubMed         Abstract available
    
    
19. DANESE S, Dignass A, Matsuoka K, Ferrante M, et al
    Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.
    J Crohns Colitis. 2024 Jun 13:jjae088. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

20. TAKAHASHI K, Morita N, Tamano R, Gao P, et al
    Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.
    J Gastroenterol. 2024 Jun 14. doi: 10.1007/s00535-024-02121.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

21. CHEN R, Zhang S
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:592.
    PubMed        
    
    
22. NOOR NM, Lee JC, Bond S, Parkes M, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial - Authors' reply.
    Lancet Gastroenterol Hepatol. 2024;9:592-594.
    PubMed        
    
    
23. BORKAR V, Lunagariya Y, Chopra S, Sasikumar D, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591.
    PubMed        
    
    
24. SATSANGI J, Nowak J, Kalla R, Colombel JF, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591-592.
    PubMed        
    
    
25. BOURGONJE AR, Visschedijk MC, Festen EAM, Weersma RK, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:590-591.
    PubMed        
    
    

    
    PLoS One

26. 
    Sources of diagnostic delay for people with Crohn's disease and ulcerative colitis: Qualitative research study.
    PLoS One. 2024;19:e0301672.
    PubMed         Abstract available
    
    
27. LI L, Zhang M, Gu M, Li J, et al
    The causal relationship between autoimmune diseases and age-related macular degeneration: A two-sample mendelian randomization study.
    PLoS One. 2024;19:e0303170.
    PubMed         Abstract available
    
    
28. CHI G, Pei J, Li X
    Inflammatory bowel disease and risk of autoimmune hepatitis: A univariable and multivariable Mendelian randomization study.
    PLoS One. 2024;19:e0305220.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.